{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zabaleta A"],"funding":["La Caixa Foundation","Cancer Research UK (A26819), FCAECC and AIRC under the Accelerator Award Programme (EDITOR)","Instituto de Salud Carlos III","Riney Family Multiple Myeloma Research Program","Instituto de Salud Carlos III/Subdirección General de Investigación Sanitaria, (cofunded by the EU)","Black Swan Research Initiative of the International Myeloma Foundation","Fundación Científica Asociación Española Contra el Cáncer","CIBER-Consorcio Centro de Investigación Biomédica en Red - Área de Oncología - Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación","CRIS Cancer Foundation"],"pagination":["93-102"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11625977"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["100(1)"],"pubmed_abstract":["The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T-cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next-generation flow in 201 patients treated in clinical trials with chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE). Achieving MRD negativity at 10<sup>-6</sup> was associated with 89% reduction in the risk of progression and/or death. Survival outcomes were improved in patients with sustained versus transient MRD negativity and were dismal in those who remained MRD positive. The intent-to-treat MRD negative rates were higher in patients treated with CAR T cells versus TCE. However, among patients achieving MRD negativity, there were no differences in survival outcomes when strati"],"journal":["American journal of hematology"],"pubmed_title":["Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy."],"pmcid":["PMC11625977"],"funding_grant_id":["PR_EX_2020‐02","PI19/01451","CB16/12/00233","ICI19/00025","PI21/01816","CP042702/LCF/PR/GN18/50310007","CB16/12/00369","CB16/12/00489","PI22/00647","PR_EX_2020-02"],"pubmed_authors":["Moreno C","Mateos MV","Puertas B","Zabaleta A","Blade J","Lopez-Corral L","Urbano A","Cedena MT","Puig N","Tamariz-Amador LE","Lopez-Munoz N","Rey-Bua B","Martinez-Lopez J","Juan M","de Larrea CF","Rodriguez-Otero P","Perez JJ","Prosper F","Miras F","Paiva B","Gonzalez-Calle V","San Miguel JF","Gonzalez-Navarro EA","Lahuerta JJ","Sanchez-Pina JM","Oliver-Caldes A"],"additional_accession":[]},"is_claimable":false,"name":"Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.","description":"The impact of measurable residual disease (MRD) in relapse/refractory multiple myeloma (RRMM) patients treated with T-cell redirecting immunotherapy is uncertain. We analyzed MRD dynamics using next-generation flow in 201 patients treated in clinical trials with chimeric antigen receptor (CAR) T cells and T-cell engagers (TCE). Achieving MRD negativity at 10<sup>-6</sup> was associated with 89% reduction in the risk of progression and/or death. Survival outcomes were improved in patients with sustained versus transient MRD negativity and were dismal in those who remained MRD positive. The intent-to-treat MRD negative rates were higher in patients treated with CAR T cells versus TCE. However, among patients achieving MRD negativity, there were no differences in survival outcomes when strati","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-18T13:09:40.281Z","creation":"2025-04-06T22:42:27.548Z"},"accession":"S-EPMC11625977","cross_references":{"pubmed":["39548827"],"doi":["10.1002/ajh.27526"]}}